rAAV2/4.hRPE65

N/A

Report date: 2023/10/26 16:59:47

Base Information

Drug NamerAAV2/4.hRPE65
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/4 vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLeber Congenital Amaurosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNantes University Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNantes University Hospital
Active IndicationsN/A
Inactive IndicationsLeber Congenital Amaurosis

Other Information

ATC CodeN/A
Related LinksN/A